Organon, a United States-based powerhouse in women's health, is confidently demonstrating its long-term commitment to the Chinese market through participation in the sixth China International Import Expo, which opened on Sunday in Shanghai and will run until Friday.

With a century-long legacy, Organon emerged as an independent company in 2021 following its spinoff from the global bio-pharmaceutical giant MSD. This year marks the company's second consecutive year attending the CIIE, which has become a showcase of China's new development paradigm and a public gauge of global prosperity, said Zafer Unluer, senior vice-president of Organon and president of Organon China.

"For Organon, the CIIE is more than just an annual event; it signifies the company's dedication to contributing to the country's healthcare landscape and supporting the well-being of Chinese women," he added.

With the theme of "Invest for Her, Invest for All", Organon has set up a 800-square-meter booth at this year's CIIE, displaying an extensive range of innovative products and solutions for the entire fertility and life cycles of women and their families. The exhibits include both China-approved treatment options and products awaiting approval, reflecting Organon's commitment to providing comprehensive healthcare solutions.

Unluer expressed his pride in participating in the CIIE for the second time. He said China's inclusiveness and economic vitality have boosted the company's confidence in the promising market, and pointed out that since its spinoff, Organon has sealed eight global business deals, with a focus on high-incidence women-specific conditions such as endometriosis and polycystic ovary syndrome. The company now is accelerating the introduction of these products and solutions to the Chinese market.

"Women are not small men; they must be treated equally depending on the prevalence of the diseases between genders. Organon is committed to making investments in areas that have been under-invested and under-resourced for a long time globally," Unluer said. "We have invested deeply in the research and development of preterm labor, postpartum hemorrhage, endometriosis and many other disease areas to change the situation for women."

The company's ambitious goal in China is to introduce at least one product or procedure annually, such as an innovative device for the treatment of postpartum hemorrhage, a condition that poses a significant threat to new mothers, according to Unluer.

Organon is also working closely with its Chinese partners in assisted reproduction and female fertility protection in a bid to support China's fertility policy.

"In China, for the Globe" is the philosophy Organon adheres to, Unluer said, adding that it shows both the company's recognition of China as its second-largest global market and demonstrates its commitment to China's healthcare ecosystem.

"Organon has seen the unmet healthcare needs of Chinese women and their families, the rapidly evolving industry and its potential to spearhead global pharmaceutical innovation," Unluer said. "By forming strategic alliances with local Chinese enterprises we aim to support their pharmaceutical R&D and help their products enter overseas markets to benefit global patients."

Instead of a one-size-fits-all approach, the company has developed strategies based on local conditions and demands. These include investments in private hospitals, the consumer healthcare market and retail channels.

At the CIIE, Organon is hosting an array of activities to build partnerships with Chinese companies and present its initiatives in academia, diagnostics and treatment, retail and digital transformation.

"The Chinese biopharmaceutical ecosystem and all the innovations happening within it are catching up with the developed markets at a fast pace, so we are aiming to seize more growth opportunities in the country with a larger capability of making investments here," Unluer said.